Earnings Beat, Increased FY22 Outlook, Rising Biosimilar Competition: Biogen’s Q2 Highlights
[ad_1] Biogen Inc BIIB has posted Q2 sales of $2.59 billion, beating the consensus of $2.48 billion, down 7% Y/Y and 5% at constant currency (CC). Multiple sclerosis revenue, including…